ADMINISTRATION OF HA-1 TCR TRANSDUCED VIRUS-SPECIFIC T-CELLSAFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITHHIGH-RISK LEUKEMIA.
- Conditions
- high risk leukemia
- Registration Number
- NL-OMON26148
- Lead Sponsor
- eiden University Medical Center (LUMC)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Age 18-75 years;
2. WHO performance score 0-2;
Exclusion Criteria
1. Life expectation < 3 months;
2. End stage irreversible multi-system organ failure;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. The number of events of acute GvHD, all other adverse events and death;<br /><br>2. The feasibility of generation of HA-1 TCR transduced virus-specific donor T-cells.
- Secondary Outcome Measures
Name Time Method 1. The number of HA-1 TCR transduced virus-specific donor T-cells in blood or bone marrow at different time points;<br /><br>2. The number of patients eligible for standard DLI at 6 months.